drugset
drugset / Trial / NCT06152861

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

NCT06152861 ↗

Phase 2 Unknown 250 enrolled Glaukos Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A low dose, medium dose and high dose of Travoprost Ophthalmic Topical Cream will be compared to timolol maleate ophthalmic solution, 0.5% and to travoprost ophthalmic solution, 0.004%.

Timeline

Start
2023-11-15
Primary completion
2024-08
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Timolol Other / unclassified 0.5 % —
Subject Travoprost Other / unclassified 0.004 % Topical

Indications

ocular hypertension open-angle glaucoma